Optimizing trial design in pharmacogenetics research: Comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements

Pharmaceutical Statistics

Volumn 12, Issue 6, 2013, Pages 366-374

  Boessen, Ruud ^a   Van Der Baan, Frederieke ^a,b   Groenwold, Rolf ^a   Egberts, Antoine ^a,b   Klungel, Olaf ^a,b   Grobbee, Diederick ^a   Knol, Mirjam ^a,b   Roes, Kit ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

adaptive trial design; pharmacogenetics; population enrichment

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); EFFECT SIZE; HUMAN; PHARMACOGENETICS; PROBABILITY SAMPLE; RANDOMIZATION; SAMPLE SIZE; SIMULATION; STUDY DESIGN;

ADAPTIVE TRIAL DESIGN; PHARMACOGENETICS; POPULATION ENRICHMENT;

CLINICAL TRIALS AS TOPIC; GENETIC MARKERS; GENOMICS; HUMANS; PHARMACOGENETICS; RESEARCH DESIGN; SAMPLE SIZE;

EID: 84887412859     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1599     Document Type: Article

References (22)

1. DiMasi JA, Hansen RW, Grabowski HG,. The price of innovation: new estimates of drug development costs. Journal of Health Economics 2003; 22 (2): 151-185. (Pubitemid 36279392)
2. Adams CP, Brantner VV,. Estimating the cost of new drug development: is it really 802 million dollars? Health Affairs (Millwood) 2006; 25 (2): 420-428. (Pubitemid 43529550)
3. Hung HM, O'Neill RT, Wang SJ, Lawrence J,. A regulatory view on adaptive/flexible clinical trial design. Biometrical Journal 2006; 48 (4): 565-573. (Pubitemid 44367896)
4. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J,. Adaptive designs in clinical drug development-an Executive Summary of the PhRMA Working Group. Journal of Biopharmaceutical Statistics 2006; 16 (3): 275-283.
5. Bretz F, Koenig F, Brannath W, Glimm E, Posch M,. Adaptive designs for confirmatory clinical trials. Statistics in Medicine 2009; 28 (8): 1181-1217.
6. Orloff J, Douglas F, Pinheiro J, Levinson S, Branson M, Chaturvedi P, Ette E, Gallo P, Hirsch G, Mehta C, Patel N, Sabir S, Springs S, Stanski D, Evers MR, Fleming E, Singh N, Tramontin T, Golub H,. The future of drug development: advancing clinical trial design. Nature Reviews Drug Discovery 2009; 8 (12): 949-957.
7. van der Baan F, Knol M, Klungel OH, Egberts AC, Grobbee DE, Roes KCB,. Potential of adaptive trial designs in pharmacogenetic research. Pharmacogenomics 2012; 13 (5): 571-578.
8. Jenkins M, Stone A, Jennison C,. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 2011; 10 (4): 347-356.
9. Wang SJ, Hung HM, O'Neill RT,. Adaptive patient enrichment designs in therapeutic trials. Biometrical Journal 2009; 51 (2): 358-374.
10. Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH,. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 2009; 119 (4): 597-605.
11. Rosenblum M, van der Laan MJ,. Optimizing randomized trial designs to distinguish which subpopulations benefit from treatment. Biometrika 2011; 98 (4): 845-860.
12. Hochberg Y,. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75 (4): 800-802.
13. O'Brien PC, Fleming TR,. A multiple testing procedure for clinical trials. Biometrics 1979; 35 (3): 549-556. (Pubitemid 10242750)
14. Wang S-J, O'Neill RT, Hung HM,. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subsets. Pharmaceutical Statistics 2007; 6 (3): 227-244. (Pubitemid 47455262)
15. Bauer P, Köhne K,. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029-1041.
16. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M,. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 2009; 361 (10): 947-957.
17. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT,. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine 2008; 5 (2): 0260-0268. (Pubitemid 351317657)
18. Adaptive design clinical trials for drugs and biologics, Draft Guidance for Industry, February 2010. http://www.fda.gov/downloads/Drugs/./Guidances/ ucm201790.pdf [Accessed January 2012].
19. Denne JS,. Sample size recalculation using conditional power. Statistics in Medicine 2001; 20 (17-18): 2645-2660. (Pubitemid 32834374)
20. Gao P, Ware JH, Mehta C,. Sample size re-estimation for adaptive sequential design in clinical trials. Journal of Biopharmaceutical Statistics 2008; 18 (6): 1184-1196.
21. Cui L, Hung HMJ, Wang SJ,. Modification of sample size in group sequential trials. Biometrics 1999; 55 (3): 853-857. (Pubitemid 29427088)
22. Lehmacher W, Wassmer G,. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55 (4): 1286-1290.